DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,978 filers reported holding DANAHER CORPORATION in Q2 2022. The put-call ratio across all filers is 1.13 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,218,466,534 | +1.2% | 49,248,152 | -2.1% | 0.35% | +5.4% |
| Q2 2023 | $12,067,774,877 | -7.3% | 50,282,395 | -2.6% | 0.33% | -13.3% |
| Q1 2023 | $13,018,026,720 | -3.5% | 51,650,638 | +1.6% | 0.38% | -9.2% |
| Q4 2022 | $13,493,832,803 | +8.2% | 50,839,548 | +5.3% | 0.42% | -0.2% |
| Q3 2022 | $12,472,401,000 | +3.5% | 48,288,359 | +1.5% | 0.42% | +9.6% |
| Q2 2022 | $12,056,402,000 | -9.5% | 47,556,018 | +4.7% | 0.39% | +7.8% |
| Q1 2022 | $13,325,135,000 | -8.3% | 45,427,110 | +2.8% | 0.36% | -3.0% |
| Q4 2021 | $14,538,673,000 | +4.7% | 44,189,145 | -3.1% | 0.37% | -4.9% |
| Q3 2021 | $13,889,008,000 | +16.9% | 45,621,495 | +3.1% | 0.39% | +17.5% |
| Q2 2021 | $11,877,836,000 | +16.3% | 44,260,836 | -2.5% | 0.33% | +10.3% |
| Q1 2021 | $10,215,312,000 | +0.6% | 45,385,243 | -0.7% | 0.30% | -7.4% |
| Q4 2020 | $10,153,866,000 | +7.3% | 45,709,313 | +4.0% | 0.32% | -7.2% |
| Q3 2020 | $9,461,905,000 | +18.7% | 43,941,424 | -2.5% | 0.35% | +9.7% |
| Q2 2020 | $7,973,259,000 | +38.2% | 45,089,961 | +8.2% | 0.32% | +12.8% |
| Q1 2020 | $5,769,834,000 | -14.7% | 41,686,536 | -5.5% | 0.28% | +8.5% |
| Q4 2019 | $6,767,922,000 | +1.6% | 44,096,442 | -4.4% | 0.26% | -7.1% |
| Q3 2019 | $6,662,865,000 | +5.2% | 46,132,125 | +4.1% | 0.28% | +3.3% |
| Q2 2019 | $6,334,571,000 | +13.2% | 44,322,514 | +4.5% | 0.27% | +8.4% |
| Q1 2019 | $5,597,768,000 | +24.4% | 42,400,893 | -2.8% | 0.25% | +10.1% |
| Q4 2018 | $4,499,639,000 | -4.6% | 43,634,997 | +0.5% | 0.23% | +11.3% |
| Q3 2018 | $4,718,836,000 | +11.1% | 43,427,529 | +0.9% | 0.20% | +4.1% |
| Q2 2018 | $4,246,272,000 | -0.4% | 43,030,711 | -1.1% | 0.20% | -3.9% |
| Q1 2018 | $4,261,685,000 | +12.0% | 43,526,564 | +6.2% | 0.20% | +12.7% |
| Q4 2017 | $3,804,169,000 | +13.1% | 40,984,366 | +4.6% | 0.18% | +6.5% |
| Q3 2017 | $3,362,137,000 | +1.6% | 39,194,892 | -0.0% | 0.17% | -2.9% |
| Q2 2017 | $3,308,239,000 | +1.9% | 39,201,798 | +3.2% | 0.18% | -1.7% |
| Q1 2017 | $3,247,398,000 | +2790.9% | 37,967,922 | +2530.9% | 0.18% | +11.9% |
| Q4 2016 | $112,333,000 | +13.5% | 1,443,127 | +14.3% | 0.16% | +12.0% |
| Q3 2016 | $98,949,000 | -24.1% | 1,262,276 | -2.2% | 0.14% | -27.6% |
| Q2 2016 | $130,369,000 | +13.5% | 1,290,779 | +6.6% | 0.20% | +5.9% |
| Q1 2016 | $114,825,000 | -31.2% | 1,210,454 | -32.7% | 0.18% | -24.5% |
| Q4 2015 | $166,934,000 | +19.4% | 1,797,296 | +9.6% | 0.24% | +11.9% |
| Q3 2015 | $139,763,000 | +14.9% | 1,640,229 | +15.4% | 0.22% | +21.7% |
| Q2 2015 | $121,662,000 | -5.8% | 1,421,454 | -6.5% | 0.18% | +1.1% |
| Q1 2015 | $129,122,000 | -19.6% | 1,520,851 | -18.8% | 0.18% | -22.6% |
| Q4 2014 | $160,566,000 | -6.9% | 1,873,358 | -17.5% | 0.23% | -8.7% |
| Q3 2014 | $172,545,000 | -2.0% | 2,270,913 | +1.6% | 0.25% | -3.8% |
| Q2 2014 | $176,013,000 | +57.7% | 2,235,664 | +50.3% | 0.26% | +45.6% |
| Q1 2014 | $111,580,000 | +2.1% | 1,487,737 | +5.1% | 0.18% | +1.1% |
| Q4 2013 | $109,328,000 | +5.2% | 1,416,160 | -5.6% | 0.18% | -9.2% |
| Q3 2013 | $103,942,000 | +5.0% | 1,499,443 | -4.2% | 0.20% | 0.0% |
| Q2 2013 | $99,029,000 | – | 1,564,437 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |